"目录号: HY-13619
Efaproxiral是一种血红蛋白 (Hb) 合成变构调节剂, 降低血红蛋白氧 (O2) 的结合亲和力。
相关产品
SBE-β-CD-MPTP hydrochloride-Cyclosporin A-Etomoxir-Auranofin-GKT137831-Ceruletide-Acetylcysteine-JC-1-BPTES-Brassinolide-FCCP-IPTG-MTT-RSL3 1S,3R--
生物活性
Description
Efaproxiral is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT.
Clinical Trial
Spectrum Pharmaceuticals, Inc
Breast Cancer-Metastases
February 2004
Phase 3
Spectrum Pharmaceuticals, Inc
Metastatic Cancer
February 2000
Phase 3
New Approaches to Brain Tumor Therapy Consortium-National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
July 2000
Phase 1-Phase 2
Spectrum Pharmaceuticals, Inc
Lung Cancer
November 2002
Phase 3
Spectrum Pharmaceuticals, Inc
Lung Cancer
October 1998
Phase 2
View MoreCollapse
References
